Clinical significance of circulating microparticles for venous thromboembolism in cancer patients

Hamostaseologie

Volumn 32, Issue 2, 2012, Pages 127-131

  Thaler, J ^a   Ay, C ^a   Pabinger, I ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Microparticles; Tissue factor; Venous thrombo embolism

Indexed keywords

LIPOCORTIN 5; PHOSPHATIDYLSERINE;

ADVANCED CANCER; ATOMIC FORCE MICROSCOPY; BLOOD CLOTTING; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; DISEASE MARKER; DYNAMIC LIGHT SCATTERING; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LIGHT SCATTERING; MEMBRANE MICROPARTICLE; PARTICLE SIZE; PREDICTION; PROSPECTIVE STUDY; REVIEW; VENOUS THROMBOEMBOLISM; ANIMAL; BIOLOGICAL MODEL; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL-DERIVED MICROPARTICLES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84866159092     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1164     Document Type: Review

References (48)

1. Castellana D, Kunzelmann C, Freyssinet JM. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression. Hämostaseologie 2009;29:51-57.
2. Siljander P, Carpen O, Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996;87:4651-4663.
3. Willekens FL, Werre JM, Groenen-Dopp YA et al. Erythrocyte vesiculation: a self-protective mechanism? Br J Haematol 2008;141:549-556.
4. Sabatier F, Roux V, Anfosso et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002;99:3962-3970.
5. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles. Eur J Clin Invest 2004;34:392-401.
6. Satta N, Freyssinet JM, Toti F. The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. Br J Haematol 1997;96:534-542.
7. Schecter AD, Spirn B, Rossikhina M et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res. 2000;87:126-132.
8. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999;30:111-142.
9. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-1662.
10. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009;22:61-69.
11. Dvorak HF, Van DeWater L, Bitzer AM et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983;43:4434-4442.
12. Harris NL, Dvorak AM, Smith J, Dvorak HF. Fibrin deposits in Hodgkin's disease. Am J Pathol 1982;108:119-129.
13. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36:888-906.
14. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988;263:18205-18212.
15. Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-1316.
16. Castellana D, Zobairi F, Martinez MC et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche. Cancer Res 2009;69:785-793.
17. Yu JL, May L, Lhotak V et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells. Blood 2005;105:1734-1741.
18. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967;13:269-288.
19. Sinauridze EI, Kireev DA, Popenko NY et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007;97:425-434.
20. Tans G, Rosing J, Thomassen MC et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991;77:2641-26418.
21. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-1611.
22. Nieuwland R, Berckmans RJ, McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-935.
23. Shet AS, Aras O, Gupta K et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
24. Osterud B. The role of platelets in decrypting monocyte tissue factor. Dis Mon 2003;49:7-13.
25. Hron G, Kollars M, Weber H et al. Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97:119-123.
26. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-2067.
27. Diamant M, Nieuwland R, Pablo RF et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002;106:2442-2447.
28. Tesselaar ME, Romijn FP, Van Der Linden IK et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527.
29. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-949.
30. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007;282:25416-25424.
31. Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 2010;77:502-514.
32. Jy W, Horstman LL, Jimenez JJ et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1842-1851.
33. Shah MD, Bergeron AL, Dong JF, Lopez JA. Flow cytometric measurement of microparticles. Platelets. 2008;19:365-372.
34. Robert S, Poncelet P, Lacroix R et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer. J Thromb Haemost 2009;7:190-197.
35. Key NS. Analysis of tissue factor positive microparticles. Thromb Res 2010;125 Suppl 1:42-45.
36. Key NS, Chantrathammachart P, Moody PW, Chang JY. Membrane microparticles in VTE and cancer. Thromb Res 2010;125 Suppl 2:80-83.
37. Lawrie AS, Albanyan A, Cardigan RA et al. Microparticle sizing by dynamic light scattering in freshfrozen plasma. Vox Sang 2009;96:206-212.
38. Aupeix K, Hugel B, Martin T et al. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997;99:1546-1554.
39. Yuana Y, Oosterkamp TH, Bahatyrova S et al. Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost 2010;8:315-323.
40. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
41. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34.
42. Manly DA, Wang J, Glover SL et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010;125:511-512.
43. Campello E, Spiezia L, Radu CM et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011;127:473-477.
44. Khorana AA, Francis CW, Menzies KE et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6:1983-1985.
45. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008;34:195-198.
46. Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res 2010;125(Suppl 2):89-91.
47. Auwerda JJ, Yuana Y, Osanto S et al. Microparticleassociated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011;105:14-20.
48. Thaler J, Ay C, Weinstabl H et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol 2011;90:447-453.